Schistosomiasis/Mycetoma
| Development of potential new pediatric treatments for schistosomiasis | Astellas is working with its partners in a consortium (Consortium partners | Pediatric Praziquantel Consortium) to develop potential new pediatric treatment options for schistosomiasis. Astellas has contributed its formulation technology to create a potential new pediatric formulation, which has been transferred to Farmanguinhos (Brazil) and Merck KGaA (Germany) for further optimization and upscaling.
Phase III clinical trials in Côte d'Ivoire and Kenya were completed in 2021, and in December 2022 the European Medicines Agency (EMA) approved to review this application for a potential new treatment option for schistosomiasis in pre-school children. Astellas will continue to provide its expertise and technology as a member of the consortium. Eisai is committed to working with consortium partners to bring its products to children in African countries where schistosomiasis is endemic. |
|---|---|
| Development of Mycetoma Therapeutics and Disease Awareness | Eisai is working with the Drugs for Neglected Diseases initiative (DNDi, headquartered in Geneva, Switzerland), an independent non-profit foundation, on Eisai's antifungal agent E1224 (foslavuconazole), which is one of the most neglected diseases in the world and was approved in 2016 as a new Eisai is conducting Phase II clinical trials in collaboration with DNDi and the Mycetoma Research Center (MRC) at the University of Khartoum, Sudan, as a novel treatment for mycetoma (eumycetoma), which was recognized as a new NTD in 2016. Eisai also supports the activities of AAR Japan, an international NGO from Japan in Sudan, a country where mycetoma is endemic, and has been collaborating with them in disease awareness and medical support since 2019. |